Global Gene Therapy Market Research Report: By Product (Kymriah, Luxturna, Yescarta, Zolgensma, Strimvelis, Zynteglo, Others), By Indication (Oncology, Genetic Diseases, Others) and By End-User (Hospitals & Clinics, Specialty Treatment Centers, Others) – Forecast to 2027

Market Forecast

Global Gene Therapy Market was valued USD 524 million in2018 and expected to register a CAGR of 40.7%.

Market Synopsis

The research and development, along with increased investment in product development is driving the global gene therapy market.

Market Influencer

Acquisitions of small-scale companies by key players and a large number of ongoing clinical trials are driving the market.

Market Drivers

• Robust product pipeline


• Increasing investment by key players


• High prevalence of target diseases and demand for innovative medication

Market Restraints

• The high cost of product development


• Stringent regulatory policies

Segmentation

By Product

• Kymriah: Novartis AG reported an annual sale of USD 28 million in 2018.


• Luxturna: Luxturna is an Adeno Associated Virus (AAV) gene therapy for the treatment of retinal dystrophy.


• Yescarta: The drug was approved by the US Food and Drug Administration (FDA), in 2018, for the treatment of B-cell lymphoma.


• Zolgensma: The brand Zolgensma has received provisional approval by the FDA for investigational product AVXS-101 (onasemnogene abeparvovec-xxxx).


• Strimvelis: The drug is indicated for the treatment of severe combined immunodeficiency arising due to adenosine deaminase deficiency (ADA-SCID).


• Zynteglo: The drug indicated for transfusion-dependent β thalassaemia (TDT), is the second most expensive drug valued at an approximate value of USD 1.8 million.


• Imlygic: It is the first oncolytic viral therapy


• Others: This segment includes drugs which are ongoing pre-clinical or clinical trials.

By Indication

• Oncology: The fastest-growing segment, due to the increasing prevalence of various types of cancer.


• Genetic Diseases/ Disorders: The largest segment, due to the high number of approved products.


• Others: Includes drugs, which are in Phase-3 of clinical trials, for indications like X-Linked Retinitis Pigmentosa, Hemophilia B, Leber Hereditary Optic Neuropathy, and Mucopolysaccharidosis Type IIIA amongst others.

By End-User

• Hospitals & Clinics: The largest segment, hospitals, and clinics are usually the primary points for diagnosis, treatment, and rehabilitation of individuals.


• Specialty Treatment Centers: A small segment, these centers provide treatments for specific diseases, for instance, cancer.


• Others: This segment includes home care and senior citizen centers.

By Region

• Americas: The largest regional market, due to the presence of key market players and high healthcare expenditure

• Europe: The growth of this region is due to product launches by key players.

• Asia-Pacific: The fastest-growing regional market, Asia-Pacific is seeing a surge in the number of people affected with diseases and rising awareness about gene therapy.

• Middle East & Africa: The smallest market due to limited healthcare infrastructure.

Key Players

• Amgen, Inc. (US)


• Novartis AG (Switzerland)


• Spark Therapeutics, Inc. (US)


• Gilead Sciences, Inc. (US)


• uniQure N.V. (Netherlands)


• Orchard Therapeutics plc (UK)


• Celgene Corporation (US)


• Bristol-Myers Squibb Company (US)


• Thermo Fisher Scientific Inc. (US)


• CEVEC (Germany)


• Lonza (Switzerland)

Frequently Asked Questions (FAQ) :

---